Category Archives: Sofosbuvir
Source: Business World The patent challenges could remove barriers to production and distribution of affordable generic versions of direct-acting antiviral medicines, which are currently sold at very high prices Patient and healthcare aid groups, including I-MAK and Delhi Network of … Continue reading
By Rupali Mukherjee, The Times of India MUMBAI: Healthcare aid and patient groups have come together in patent courts to fight against “abusive strategies” of Big Pharma, to ensure access to affordable treatment in hepatitis C. The Initiative for Medicines, … Continue reading
Source: MSF Access Campaign New Delhi/New York, 14 February 2017–Five new challenges against patents on crucial new medicines to treat hepatitis C filed in India and Argentina are the latest in a global push to ensure access to affordable treatment. … Continue reading
The World Health Organization (WHO) recently reported that over one million people in low- and middle-income countries have been treated with a revolutionary new cure for hepatitis C since its introduction two years ago.
A writ petition was filed before the Delhi High Court by I-MAK and DNP+, challenging the grant of patent to costly Hepatitis-C drug, Sofosbuvir. The first hearing for the case was expected take place on 13th September. However, the hearing has … Continue reading
By Vishakh Unnikrishnan, The CatchNews | May 14, 2016 Landing a blow to efforts to make vital drugs more affordable, the Indian Patent Office has granted the American pharmaceutical company Gilead a patent for sofosbuvir, which is used to treat … Continue reading
By Vidya Krishnan, The Hindu | May 10, 2016 The decision is a major blow to the access to drug movement, says MSF In direct contradiction to its earlier order, the Controller General of Patents, Designs and Trademark granted American … Continue reading